SOHO 2025 | Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, comments on the potential for treatment-free remission (TFR) in patients with acute lymphoblastic leukemia (ALL) who have achieved complete molecular remission. Dr Abruzzese highlights that while ALL is different from chronic myeloid leukemia (CML), some patients with ALL can maintain remission after stopping treatment. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a big subject that we are addressing in the international community right now because as we were used to with CML to enter TFR for those patients, we have patients with ALL that have been treated for many many years and they are in complete molecular remission but we are always afraid because ALL is not CML and so there are different trials and also some data that were harvested on this subject...
This is a big subject that we are addressing in the international community right now because as we were used to with CML to enter TFR for those patients, we have patients with ALL that have been treated for many many years and they are in complete molecular remission but we are always afraid because ALL is not CML and so there are different trials and also some data that were harvested on this subject. And usually when people relapse, they can respond to the drug that they were given before the suspension. Mainly we are talking about, of course, TKIs. And don’t forget that now we also have the possibility to include in the treatment at baseline monoclonal antibodies that can manage the minimal residual disease and probably give something that is helpful in maintaining this CR. Also molecular biology techniques, the newest ones, the NGS, are promising because they can identify, together with the digital PCR, a very low level of illness. And so they can better select patients that can enter TFR and hopefully stay on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
